Expression and activity of antioxidants in the brain in progressive supranuclear palsy

Brain Research

Volumn 930, Issue 1-2, 2002, Pages 170-181

  Cantuti Castelvetri, Ippolita ^a   Keller McGandy, Christine E ^a   Albers, David S ^b   Beal, M Flint ^b   Vonsattel, Jean Paul ^a   Standaert, David G ^a   Augood, Sarah J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Neurodegeneration; Oxidative stress; Parkinsonism; Progressive supranuclear palsy; Superoxide dismutase; Tau

Indexed keywords

ANTIOXIDANT; BRAIN ENZYME; GLUTATHIONE; PARAFFIN; SUPEROXIDE DISMUTASE;

ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN; BRAIN LEVEL; CADAVER; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITY; DISEASE COURSE; ENZYME ACTIVITY; ENZYME ASSAY; GLIA; GLUTATHIONE METABOLISM; HUMAN; HUMAN TISSUE; IMMUNOLOCALIZATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SUBTHALAMIC NUCLEUS; TISSUE DISTRIBUTION; TISSUE SECTION; WHITE MATTER;

ANTIOXIDANTS; BLOTTING, WESTERN; BRAIN; BRAIN CHEMISTRY; BUFFERS; GLUTATHIONE; HUMANS; IMMUNOHISTOCHEMISTRY; NEURONS; OXIDATIVE STRESS; PARAFFIN EMBEDDING; SUPEROXIDE DISMUTASE; SUPRANUCLEAR PALSY, PROGRESSIVE;

EID: 0037087096     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(02)02244-8     Document Type: Article

References (50)

1. New insights into progressive supranuclear palsy
2. Evidence for oxidative stress in the subthalamic nucleus in progressive supranuclear palsy
3. Frontal lobe dysfunction in progressive supranuclear palsy: Evidence for oxidative stress and mitochondrial impairment
4. Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease
5. Further evidence for mitochondrial dysfunction in progressive supranuclear palsy
6. Association of an extended haplotype in the tau gene with progressive supranuclear palsy
7. Energetics in the pathogenesis of neurodegenerative diseases
8. The free radical theory of aging matures
9. Copper/zinc superoxide dismutase expression in the human central nervous system. Correlation with selective neuronal vulnerability
10. Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia
11. Neurofibrillary pathology in progressive supranuclear palsy (PSP)
12. Enzymatic/nonenzymatic sources of oxyradicals and regulation of antioxidant defenses
13. Genetic evidence for the involvement of tau in progressive supranuclear palsy
14. The clinical and pathological spectrum of Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy): A reappraisal
15. Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia
16. Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration
17. Neurodegenerative disorders with extensive tau pathology: A comparative study and review
18. Epitope expression and hyperphosphorylation of tau protein in corticobasal degeneration: Differentiation from progressive supranuclear palsy
19. Superoxide radical and superoxide dismutases
20. Multiple isoforms of human microtubule-associated protein tau: Sequences and localization in neurofibrillary tangles of Alzheimer's disease
21. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: Differential expression of tau protein mRNAs in human brain
22. Oxidative stress: Free radical production in neural degeneration
23. L-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress
24. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy)
25. Antioxidant enzyme expression in rat lungs during hyperoxia
26. Glial cells protect neurons against oxidative stress via transcriptional up-regulation of the glutathione synthesis
27. Manganese superoxide dismutase overexpression attenuates MPTP toxicity
28. Inducible nitric oxide synthase (iNOS)-like immunoreactivity in argyrophilic, tau-positive astrocytes in progressive supranuclear palsy
29. Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice
30. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders [see comments]
31. Clinical and genetic aspects of progressive supranuclear palsy
32. Deficit of brain and skeletal muscle bioenergetics in progressive supranuclear palsy shown in vivo by phosphorus magnetic resonance spectroscopy
33. 4-Hydroxynonenal, a product of lipid peroxidation, inhibits dephosphorylation of the microtubule-associated protein tau
34. The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase
35. Lipoperoxidation is selectively involved in progressive supranuclear palsy
36. Superoxide dismutase is an abundant component in cell bodies, dendrites, and axons of motor neurons and in a subset of other neurons
37. Glutathione is present in high concentrations in cultured astrocytes but not in cultured neurons
38. Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: Tau pathologies with exclusively 'exon 10' isoforms
39. Differential regulation of antioxidant enzymes in response to oxidants
40. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia
41. Strategies of antioxidant defense
42. Histochemical evaluation of glutathione in brain
43. Intracellular localization of the copper-zinc and manganese superoxide dismutases in rat liver parenchymal cells
44. Progressive supranuclear palsy
45. Mitochondrial dysfunction in cybrid lines expressing mitochondrial genes from patients with progressive supranuclear palsy
46. Formation of superoxide radicals by the nuclear membranes of human brain tumors
47. Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders
48. Progressive supranuclear palsy: A clinicopathological study of 21 cases
49. Fasting-induced depletion of glutathione in the aging mouse
50. An immunohistochemical study on manganese superoxide dismutae in Parkinson's disease